Nabriva Therapeutics Stock Forecast, Price & News

Nabriva Therapeutics (NASDAQ:NBRV) Frequently Asked Questions

Is Nabriva Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Nabriva Therapeutics stock.
View analyst ratings for Nabriva Therapeutics or view top-rated stocks.

How has Nabriva Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Nabriva Therapeutics' stock was trading at $1.21 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NBRV shares have decreased by 58.6% and is now trading at $0.5010.
View which stocks have been most impacted by COVID-19.

Are investors shorting Nabriva Therapeutics?

Nabriva Therapeutics saw a drop in short interest in December. As of December 31st, there was short interest totaling 885,800 shares, a drop of 20.2% from the December 15th total of 1,110,000 shares. Based on an average daily trading volume, of 813,700 shares, the days-to-cover ratio is presently 1.1 days.
View Nabriva Therapeutics' Short Interest.

When is Nabriva Therapeutics' next earnings date?

Nabriva Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Nabriva Therapeutics.

How were Nabriva Therapeutics' earnings last quarter?

Nabriva Therapeutics plc (NASDAQ:NBRV) announced its earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.21) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.22) by $0.01. The biotechnology company earned $8.86 million during the quarter, compared to the consensus estimate of $8.90 million. Nabriva Therapeutics had a negative net margin of 245.41% and a negative trailing twelve-month return on equity of 98.31%.
View Nabriva Therapeutics' earnings history.

What price target have analysts set for NBRV?

2 analysts have issued 12-month price objectives for Nabriva Therapeutics' shares. Their forecasts range from $6.00 to $6.00. On average, they expect Nabriva Therapeutics' stock price to reach $6.00 in the next year. This suggests a possible upside of 1,097.6% from the stock's current price.
View analysts' price targets for Nabriva Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Nabriva Therapeutics' key executives?

Nabriva Therapeutics' management team includes the following people:

• Theodore R. Schroeder, Chief Executive Officer & Director (LinkedIn Profile)
• Steven P. Gelone, President, Chief Operating Officer & Director
• Dan Dolan, Chief Financial Officer
• Christine Guico-Pabia, Chief Medical Officer
• Kim Anderson, Investor Contact

Who are some of Nabriva Therapeutics' key competitors?

Some companies that are related to Nabriva Therapeutics include Rani Therapeutics (RANI), Axsome Therapeutics (AXSM), Vectura Group (VEGPF), Merus (MRUS), CannTrust (CNTTF), Reata Pharmaceuticals (RETA), MannKind (MNKD), Revance Therapeutics (RVNC), Vaxxinity (VAXX), Organogenesis (ORGO), Crinetics Pharmaceuticals (CRNX), BELLUS Health (BLUSF), Zealand Pharma A/S (ZEAL), Day One Biopharmaceuticals (DAWN) and Atai Life Sciences (ATAI).
View all of NBRV's competitors.

What other stocks do shareholders of Nabriva Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nabriva Therapeutics investors own include SCYNEXIS (SCYX), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), Acasti Pharma (ACST), Amarin (AMRN), AcelRx Pharmaceuticals (ACRX), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and Heat Biologics (HTBX).

What is Nabriva Therapeutics' stock symbol?

Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."

Who are Nabriva Therapeutics' major shareholders?

Nabriva Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include XR Securities LLC (0.00%). Company insiders that own Nabriva Therapeutics stock include Colin Md Broom, J Christopher Naftzger, Stephen W Webster, Theodore R Schroeder and Theodore R Schroeder.
View institutional ownership trends for Nabriva Therapeutics.

Which institutional investors are buying Nabriva Therapeutics stock?

NBRV stock was bought by a variety of institutional investors in the last quarter, including XR Securities LLC. Company insiders that have bought Nabriva Therapeutics stock in the last two years include J Christopher Naftzger, and Theodore R Schroeder.
View insider buying and selling activity for Nabriva Therapeutics or or view top insider-buying stocks.

How do I buy shares of Nabriva Therapeutics?

Shares of NBRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nabriva Therapeutics' stock price today?

One share of NBRV stock can currently be purchased for approximately $0.50.

How much money does Nabriva Therapeutics make?

Nabriva Therapeutics has a market capitalization of $272.13 million and generates $5.03 million in revenue each year. The biotechnology company earns $-69.48 million in net income (profit) each year or ($2.14) on an earnings per share basis.

How many employees does Nabriva Therapeutics have?

Nabriva Therapeutics employs 72 workers across the globe.

What is Nabriva Therapeutics' official website?

The official website for Nabriva Therapeutics is www.nabriva.com.

Where are Nabriva Therapeutics' headquarters?

Nabriva Therapeutics is headquartered at 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406.

How can I contact Nabriva Therapeutics?

Nabriva Therapeutics' mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406. The biotechnology company can be reached via phone at (531) 649-2000, via email at [email protected], or via fax at 610-816-6639.